Table 1:
Patients characteristics.
| Patient | Age, years | Sex | Origin of peritoneal metastasis | PCI | Number of (e)PIPAC | Systemic chemotherapy | Radiological response (RECIST) | Histological response of PM (PRGS) | Adverse events (CTCAE) | Survival (months) from diagnosis | Survival (months) from (e)PIPAC #1 |
| 1 AL | 72 | M | CUP (HBP) | 17 | 2 PIPAC 2 ePIPAC | 3 cycles Cisplatin + Gemcitabin weekly, discontinued | Partial response(PM) | PRGS 2 Major regression | 2 (AP) | 11,1 | 9,1 |
| 2 BC | 68 | W | Pancreas | 3 | 2 PIPAC 1 ePIPAC | 7 cycles Nab-paclitaxel + Gemcitabin, discontinued | N/A (PM); Stable disease (primary) | PRGS 1 Complete regression | 1 (AP) | 11,7 | 8,6 |
| 3 ER | 59 | W | Gallbladder | 3 | 6 PIPAC 1 ePIPAC | 13 cycles Cisplatin + Gemcitabin | N/A (PM); Partial response (primary) | PRGS 1 Complete regression | 1 (AP) | >22 (alive) | >18 (alive) |
PM, peritoneal metastasis; PCI, peritoneal carcinomatosis index (Sugarbaker); CUP, cancer unknown origin; HBP, hepatobiliarypancreatic; RECIST, Response Evaluation Criteria In Solid Tumors Version 1.1; PRGS, Peritoneal Regression Grading Score; CTCAE, Common Terminology Criteria for Adverse Events v. 4.03; AP, abdominal pain; (e)PIPAC, (electrostatic precipitation) PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy).